Repligen (NASDAQ:RGEN) Price Target Cut to $200.00 by Analysts at JPMorgan Chase & Co.

Repligen (NASDAQ:RGEN) had its target price lowered by investment analysts at JPMorgan Chase & Co. from $230.00 to $200.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 22.65% from the stock’s current price.

Several other research firms have also recently commented on RGEN. Stifel Nicolaus raised their target price on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. KeyCorp increased their target price on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Repligen has an average rating of “Moderate Buy” and a consensus price target of $195.70.

Repligen Trading Up 3.0 %

Shares of NASDAQ RGEN traded up $4.70 during mid-day trading on Thursday, hitting $163.06. The stock had a trading volume of 321,879 shares, compared to its average volume of 535,742. The firm has a market cap of $9.11 billion, a P/E ratio of 226.23, a price-to-earnings-growth ratio of 5.38 and a beta of 1.03. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 7.02. The business has a 50 day moving average price of $181.94 and a two-hundred day moving average price of $173.85. Repligen has a 1 year low of $110.45 and a 1 year high of $211.13.

Repligen (NASDAQ:RGEN) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.01). The business had revenue of $151.31 million during the quarter, compared to the consensus estimate of $150.06 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The firm’s revenue for the quarter was down 17.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.64 earnings per share. On average, equities analysts anticipate that Repligen will post 1.46 EPS for the current fiscal year.

Insider Transactions at Repligen

In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the sale, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CEO Anthony Hunt sold 16,707 shares of the company’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the transaction, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the sale, the vice president now owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 25,597 shares of company stock valued at $5,039,532. Insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

Several hedge funds and other institutional investors have recently bought and sold shares of RGEN. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its position in Repligen by 130.0% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 11,500 shares of the biotechnology company’s stock valued at $1,829,000 after purchasing an additional 6,500 shares during the period. Raymond James & Associates boosted its stake in shares of Repligen by 3.5% in the 3rd quarter. Raymond James & Associates now owns 67,219 shares of the biotechnology company’s stock worth $10,688,000 after buying an additional 2,283 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Repligen by 13.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company’s stock worth $190,117,000 after buying an additional 137,220 shares during the last quarter. Forsta AP Fonden bought a new stake in shares of Repligen in the third quarter worth $1,908,000. Finally, Verdence Capital Advisors LLC increased its position in Repligen by 6.7% during the third quarter. Verdence Capital Advisors LLC now owns 2,163 shares of the biotechnology company’s stock valued at $344,000 after acquiring an additional 135 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.